PURCHASE, NEW YORK – July 23, 2014 – JDS Therapeutics and its subsidiary, Nutrition 21, LLC (“Nutrition 21”) announced today that they have entered into a confidential settlement and license agreement with SuperNutrition Life-Extension Research, Inc. (“SuperNutrition”).

The settlement ends a patent and trademark infringement lawsuit brought by Nutrition 21 against SuperNutrition in the Southern District of New York related to SuperNutrition’s use of Nutrition 21’s Chromax trademark and chromium polynicotinate in their branded multivitamin products.The terms of the settlement are confidential, however, in conjunction with the settlement, SuperNutrition has agreed to license Nutrition 21’s various chromium polynicotinate patents and its Chromax and Niachrome trademarks and utilize Nutrition 21’s Niachrome brand of chromium polynicotinate for its applicable formulation needs.

Gregg Bresner, Chief Financial Officer of Nutrition 21, stated, “We are delighted that we were able to reach a customer-driven solution with respect to our dispute with SuperNutrition.  SuperNutrition has been an innovative company in the market for decades and we are excited to provide Niachrome to SuperNutrition for use in its branded family of multivitamin products. We believe this reaffirms the strength of Nutrition 21’s trademarks, and its patent portfolio which covers compositions and uses of a number of our products, including our Niachrome chromium polynicotinate.”

About Nutrition 21, LLC

Nutrition 21, a wholly owned subsidiary of JDS Therapeutics, is a leader in the nutritional supplement industry. The Company is a developer and marketer of efficacious, high-value, clinically substantiated ingredients for dietary supplements, medical foods and beverages, including its Chromax chromium picolinate, Niachrome chromium polynicotinate and Nitrosigine.  With many years of biotechnology and pharmaceutical experience, the Company’s scientific platform has created unique, patentable products that are safe and clinically effective. Rigorous preclinical and clinical trials are a key part of its product development strategy to ensure product safety and consumer trust.

Nutrition 21 currently holds over 100 domestic and international issued and pending patents for products. Many support unique claims associated with, among others, glucose metabolism, weight management, brain health, and cardiovascular health.

For more information please visit:

Contact Information:

Gregg Bresner
Nutrition 21, LLC
Chief Financial Officer

Bill Levi
Nutrition 21, LLC
VP, Strategy and Business Development
914 701-4549